TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
TTX-080-001 is a Phase 1, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase 2 dose of TTX-080 monotherapy (HLA-G inhibitor) and in combination with either pembrolizumab (PD-1 inhibitor), cetuximab (EGFR inhibitor) or FOLFIRI plus cetuximab (EGFR inhibitor) in patients with advanced refractory / resistant solid malignancies including metastatic colorectal cancer (mCRC) patients.
Checked against the public recordLast updated Feb 18, 2026 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 1
- Sponsor
- Tizona Therapeutics, Inc
- Interventions being studied
- Drug: TTX-080; Drug: TTX-080; Drug: pembrolizumab; Drug: cetuximab; Drug: FOLFIRI; Drug: cetuximab; Drug: TTX-080
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Abbreviated Inclusion Criteria: 1. Subject with histological diagnosis of advanced/metastatic cancer \[currently enrolling in CRC only\] 2. Age 18 years or older, is willing and able to provide informed consent 3. Evidence of measurable disease 4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 AND life expectancy of at least 12 weeks Abbreviated Exclusion Criteria: 1. History of allergy or hypersensitivity to study treatment components. Subjects with a history of severe hypersensitivity reaction to any monoclonal antibody 2. Use of an investigational agent within 28 days prior to the first dose of study treatment and throughout the study 3. Receiving high-dose systemic steroid therapy or any other form of immunosuppressive therapy 4. History of severe autoimmune disease 5. Uncontrolled intercurrent illness or other active malignancy requiring ongoing treatment
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Arizona Oncology AssociatesTucson, Arizona
- University of Southern CaliforniaLos Angeles, California
- Hoag Memorial HospitalNewport Beach, California
- Rocky Mountain Cancer CentersDenver, Colorado
- Yale Cancer CenterNew Haven, Connecticut
- Christiana Care Helen F. Graham Cancer CenterNewark, Delaware
- John Hopkins Kimmer Cancer CenterWashington D.C., District of Columbia
- Florida Cancer SpecialistsDaytona Beach, Florida
- Florida Cancer SpecialistsFleming Island, Florida
- Ocala Oncology CenterOcala, Florida
- AdventHealth Research InstituteOrlando, Florida
- Illinois Cancer SpecialistsArlington Heights, Illinois
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Feb 18, 2026. Always confirm current availability with the study team.